119TiP An observational study to assess the effectiveness and safety of cemiplimab in patients with advanced non-small cell lung cancer (NSCLC) in routine clinical practice within Europe (CEMI-LUNG)

Abstract

Blockade of the PD-1 pathway is the mainstay for the first-line (1L) treatment of patients (pts) with advanced NSCLC without targetable oncogenic alterations. Cemiplimab is a PD-1 inhibitor and has improved overall survival (OS) and progression-free survival (PFS) vs chemotherapy in 1L advanced NSCLC patients with high PD-L1 expression (PD-L1 ≥50%) who are without driver mutations based on the EMPOWER-Lung 1 study. Cemiplimab was subsequently licensed as monotherapy in this front line pt population by the FDA (Feb 2021) and EMA (May 2021) based on results from EMPOWER-Lung 1.